← Back to Screener
Cytokinetics Inc. (CYTK)
Price$73.68
Value ScoreF
Growth ScoreA
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)4.95%
Price vs S&P 500 (4W)16.20%
VGM Score53.96
Market Capitalization$9.55B
All Metrics
Book Value / Share (Quarterly)$0.92
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-2.37%
Cash Flow / Share (Quarterly)$-4.41
Price vs S&P 500 (YTD)9.87%
Net Profit Margin (TTM)-784.02%
EPS (TTM)$-6.84
10-Day Avg Trading Volume1.84M
EPS Excl Extra (TTM)$-6.84
Revenue Growth (5Y)9.55%
EPS (Annual)$-6.54
ROI (Annual)-55.49%
Net Profit Margin (5Y Avg)-2357.67%
Cash / Share (Quarterly)$6.58
Revenue Growth QoQ (YoY)1125.78%
ROA (Last FY)-55.10%
Revenue Growth TTM (YoY)450.60%
EBITD / Share (TTM)$-6.19
ROE (5Y Avg)-141.97%
Operating Margin (TTM)-719.65%
Cash Flow / Share (Annual)$-4.35
P/B Ratio87.63x
P/B Ratio (Quarterly)58.24x
Net Income / Employee (Annual)$-1,166,400
EV / Revenue (TTM)100.02x
Net Interest Coverage (TTM)-14.32x
ROA (TTM)-61.91%
EV / EBITDA (TTM)1261.52x
EPS Incl Extra (Annual)$-6.54
Current Ratio (Annual)4.53x
Quick Ratio (Quarterly)4.14x
3-Month Avg Trading Volume2.24M
52-Week Price Return145.08%
Revenue / Employee (TTM)$157,200
Tangible BV / Share (Quarterly)$-4.56
P/S Ratio (Annual)108.49x
Asset Turnover (Annual)0.06x
52-Week High$80.20
Operating Margin (5Y Avg)-2191.85%
EPS Excl Extra (Annual)$-6.54
CapEx CAGR (5Y)17.56%
26-Week Price Return20.88%
Quick Ratio (Annual)4.45x
13-Week Price Return22.56%
Total Debt / Equity (Annual)0.59x
Current Ratio (Quarterly)4.21x
Enterprise Value$10.58B
Revenue / Share Growth (5Y)-3.26%
Asset Turnover (TTM)0.08x
Book Value / Share Growth (5Y)10.66%
Revenue / Employee (Annual)$130,800
Pretax Margin (Annual)-891.60%
Cash / Share (Annual)$7.18
3-Month Return Std Dev49.27%
Net Income / Employee (TTM)$-1,232,700
ROE (Last FY)-88.27%
Net Interest Coverage (Annual)-12.29x
EPS Basic Excl Extra (Annual)$-6.54
P/FCF (TTM)166.49x
Receivables Turnover (TTM)23.94x
Total Debt / Equity (Quarterly)6.01x
EPS Incl Extra (TTM)$-6.84
Receivables Turnover (Annual)5.12x
ROI (TTM)-18.72%
P/S Ratio (TTM)90.27x
Pretax Margin (5Y Avg)-2357.67%
Revenue / Share (Annual)$0.73
Tangible BV / Share (Annual)$-1.14
Price vs S&P 500 (52W)116.88%
Year-to-Date Return20.81%
5-Day Price Return-0.23%
EPS Normalized (Annual)$-6.54
ROA (5Y Avg)-44.98%
Net Profit Margin (Annual)-891.60%
Month-to-Date Return19.99%
Cash Flow / Share (TTM)$-5.44
EBITD / Share (Annual)$-6.02
Operating Margin (Annual)-833.16%
LT Debt / Equity (Annual)0.59x
ROI (5Y Avg)-67.84%
LT Debt / Equity (Quarterly)5.90x
EPS Basic Excl Extra (TTM)$-6.84
P/B Ratio (Annual)15.68x
Pretax Margin (TTM)-784.02%
Book Value / Share (Annual)$2.88
Price vs S&P 500 (13W)12.81%
Beta0.40x
P/FCF (Annual)269.97x
Revenue / Share (TTM)$0.86
ROE (TTM)-131.19%
52-Week Low$30.02
vGradeF
gGradeA
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-1.67est. -1.69
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.04
4.04
4.04
4.04
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CYTKCytokinetics Inc. | F | A | B | $73.68 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Cytokinetics is a late-stage biopharmaceutical company developing small-molecule muscle activators and inhibitors for serious cardiovascular and neuromuscular diseases, including heart failure, amyotrophic lateral sclerosis, spinal muscular atrophy, and chronic obstructive pulmonary disease. Its investigational medicines enhance muscle function and contractility in patients with compromised muscle performance. The company targets large patient populations with significant unmet medical needs and limited treatment options.